利心丸联合沙库巴曲缬沙坦钠治疗慢性心力衰竭的临床研究  

Clinical study of Lixin Pills combined with sacurabatril valsartan sodium in treatment of chronic heart failure

作　　者：王朝远 李仕颖 WANG Chao-yuan;LI Shi-ying(Department of Cardiology,Xinye People's Hospital,Nanyang 473500,China;Department of Internal Medicine,Xinye People's Hospital,Nanyang 473500,China)

机构地区：[1]新野县人民医院心内科,河南南阳473500 [2]新野县人民医院内科,河南南阳473500

出　　处：《现代药物与临床》2020年第10期2028-2032,共5页Drugs & Clinic

摘　　要：目的观察利心丸联合沙库巴曲缬沙坦钠治疗慢性心力衰竭的临床疗效。方法选取2018年1月—2019年12月在新野县人民医院治疗慢性心力衰竭患者91例为研究对象,采用随机数字表法将91例慢性心力衰竭患者分为对照组(46例)和治疗组(45例)。对照组口服沙库巴曲缬沙坦钠片,50 mg/次,2次/d,后期根据患者具体病情,每2~4周倍增1次,直至200 mg/次,2次/d。治疗组在对照组基础上口服利心丸,3 g/次,3次/d。两组患者连续治疗4周。观察两组临床疗效,比较两组的6 min步行实验(6 MWT)、心功能指标、血清学指标。结果治疗后,治疗组总有效率(95.56%)高于对照组(80.43%)(P<0.05)。治疗后,两组6MWT均较治疗前增加(P<0.05),且治疗组6MWT高于对照组(P<0.05)。治疗后,两组左心室射血分数(LVEF)、每搏输出量(SV)、心输出量(CO)较治疗前均升高,且治疗组LVEF、SV、CO高于对照组(P<0.05)。治疗后,两组患者心型脂肪酸结合蛋白(H-FABP)、细胞间黏附分子-1(ICAM-1)水平较治疗前均降低(P<0.05),且治疗组H-FABP、ICAM-1水平低于对照组(P<0.05)。结论利心丸联合沙库巴曲缬沙坦钠片治疗慢性心力衰竭疗效确切,可提高运动耐量,改善心功能,降低H-FABP、ICAM-1水平。Objective To observe the clinical effect of Lixin Pills combined with Sacubitril Valsartan Sodium Tablets in treatment of chronic heart failure. Methods Patients(91 cases) with chronic heart failure in Xinye People’s Hospital from January 2018 to December 2019 were randomly divided into the control group(46 cases) and the treatment group(45 cases). Patients in the control group were po administered with Sacubitril Valsartan Sodium Tablets, 50 mg/time, twice daily, after that, according to the specific condition of the patient, it was doubled every 2 — 4 weeks until 200 mg/time, twice daily. Patients in the treatment group were po administered with Lixin Pills on the basis of the control group, 3 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and 6 MWT, cardiac function indexes, and serological indexes in two groups were compared. Results After treatment, the total effective rate of the treatment group(95.56%) was higher than that of the control group(80.43%)(P < 0.05). After treatment, 6 MWT in both groups increased significantly(P < 0.05), and the 6 MWT in the treatment group was higher than that in the control group(P < 0.05). After treatment, LVEF, SV, and CO in two groups were significantly increased, and LVEF, SV, and CO in the treatment group were higher than those in the control group(P < 0.05). After treatment, the levels of H-FABP and ICAM-1 in two groups were significantly decreased(P < 0.05), and the levels of H-FABP and ICAM-1 in the treatment group were lower than those in the control group(P < 0.05). Conclusion Lixin Pills combined with Sacubitril Valsartan Sodium Tablets has clinical curative effect in treatment of chronic heart failure, can improve exercise tolerance, improve cardiac function, and reduce the level of H-FABP and ICAM-1.

关 键 词：利心丸 沙库巴曲缬沙坦钠片 慢性心力衰竭 6 min步行实验 心功能指标 血清学指标 

分 类 号：R972[医药卫生—药品]